Comparison of fecal calprotectin levels and endoscopic scores for predicting relapse in patients with ulcerative colitis in remission

Table 1 Baseline patient characteristics

Characteristic	All, n = 75
Age in yr, median [IQR]	49 [36, 62]
Male/Female, n (%)	45 (60.0)/30 (40.0)
Disease duration in yr, median [IQR]	8 [5, 13]
Disease extent, n (%)
Extensive colitis	45 (60.0)
Left-sided colitis	24 (32.0)
Proctitis	6 (8.0)
CAI by the Rachmilewitz index, median [IQR]	0 [0, 1]
MES, n (%)
MES 0	43 (57.3)
MES 1	32 (42.7)
UCEIS, n (%)
UCEIS 0	39 (52.0)
UCEIS 1	17 (22.7)
UCEIS 2	13 (17.3)
UCEIS 3	6 (8.0)
UCCIS, median [IQR]	0 [0, 6.7]
FC in mg/kg, median [IQR]	174 [43, 810]
Medication used during the study, n (%)
Oral 5-ASA	48 (64.0)
Suppository steroids	2 (2.7)
Systemic steroids	9 (12.0)
Immunomodulators	23 (30.7)
Biologics	30 (40.0)

5-ASA: 5-aminosalicylic acid; CAI: Clinical activity index; FC: Fecal calprotectin; IQR: Interquartile range; MES: Mayo Endoscopic Subscore; UCCIS: Ulcerative Colitis Colonoscopic Index of Severity; UCEIS: Ulcerative Colitis Endoscopic Index of Severity.